IN VITRO METABOLISM AND NON-CLINICAL ADME STUDIES IDIQ CONTRACT. POP 9/27/21-9/26/26. NTE $3.5 MILLION.

Sri International, Menlo Park CA

Investigators

Abstract

The Division of Therapeutics and Medical Consequences (DTMC) of the National Institute on Drug Abuse (NIDA) supports research and development of new medications for the treatment of drug addiction. Medication development involves in vitro evaluations, nonclinical pharmacology and toxicology studies, pharmaceutical development, and clinical evaluation of new medications for treating addiction.